Article Versions Notes

Gómez-Castañeda E, Hopcroft LEM, Rogers S, Munje C, Bittencourt-Silvestre J, Copland M, Vetrie D, Holyoake T, Jørgensen HG. Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy. Cancers. 2022; 14(21):5253. https://doi.org/10.3390/cancers14215253

Gómez-Castañeda, Eduardo, Lisa E. M. Hopcroft, Simon Rogers, Chinmay Munje, Joana Bittencourt-Silvestre, Mhairi Copland, David Vetrie, Tessa Holyoake, and Heather G. Jørgensen. 2022. "Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy" Cancers 14, no. 21: 5253. https://doi.org/10.3390/cancers14215253

Gómez-Castañeda, E., Hopcroft, L. E. M., Rogers, S., Munje, C., Bittencourt-Silvestre, J., Copland, M., Vetrie, D., Holyoake, T., & Jørgensen, H. G. (2022). Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy. Cancers, 14(21), 5253. https://doi.org/10.3390/cancers14215253